Terms: = Sarcomas AND TSC1, KIAA0243, 7248, ENSG00000165699, TSC, MGC86987, LAM, hamartin
60 results:
1. Conjunctival leiomyosarcoma: A clinico-pathological study with in deep molecular characterization.
Santoro A; Angelico G; Mulè A; Minucci A; Giannuzzi F; Sammarco MG; Pagliara MM; Blasi MA
Pathol Res Pract; 2024 Mar; 255():155182. PubMed ID: 38335782
[TBL] [Abstract] [Full Text] [Related]
2. Glycoprotein Nonmetastatic Melanoma Protein B (GPNMB) Immunohistochemistry Can Be a Useful Ancillary Tool to Identify Perivascular Epithelioid Cell Tumor.
Wangsiricharoen S; Ingram DR; Morey RR; Wani K; Lazar AJ; Wang WL
Mod Pathol; 2024 Mar; 37(3):100426. PubMed ID: 38219952
[TBL] [Abstract] [Full Text] [Related]
3. sarcomas With RAD51B Fusions Are Associated With a Heterogeneous Phenotype.
Chang HY; Dermawan J; Sharma A; Dickson B; Turashvili G; Torrence D; Nucci M; Chiang S; Oliva E; Kirchner M; Stenzinger A; Mechtersheimer G; Antonescu C
Mod Pathol; 2024 Feb; 37(2):100402. PubMed ID: 38141829
[TBL] [Abstract] [Full Text] [Related]
4. Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.
Subbiah V; Coleman N; Piha-Paul SA; Tsimberidou AM; Janku F; Rodon J; Pant S; Dumbrava EEI; Fu S; Hong DS; Zhang S; Sun M; Jiang Y; Roszik J; Song J; Yuan Y; Meric-Bernstam F; Naing A
Cancer Res Commun; 2024 Feb; 4(2):378-387. PubMed ID: 38126764
[TBL] [Abstract] [Full Text] [Related]
5. A Phase I/II Investigation of Safety and Efficacy of Nivolumab and
Gordon EM; Angel NL; Omelchenko N; Chua-Alcala VS; Moradkhani A; Quon D; Wong S
Anticancer Res; 2023 May; 43(5):1993-2002. PubMed ID: 37097693
[TBL] [Abstract] [Full Text] [Related]
6. A rare metastatic mesenteric malignant PEComa with tsc2 mutation treated with palliative surgical resection and nab-sirolimus: a case report.
Meredith L; Chao T; Nevler A; Basu Mallick A; Singla RK; McCue PA; Bowne WB; Jiang W
Diagn Pathol; 2023 Apr; 18(1):45. PubMed ID: 37041531
[TBL] [Abstract] [Full Text] [Related]
7. A Clinicopathologic and Molecular Characterization of Uterine sarcomas Classified as Malignant PEComa.
Anderson WJ; Dong F; Fletcher CDM; Hirsch MS; Nucci MR
Am J Surg Pathol; 2023 May; 47(5):535-546. PubMed ID: 36856023
[TBL] [Abstract] [Full Text] [Related]
8. Autophagy inhibition prevents lymphatic malformation progression to lymphangiosarcoma by decreasing osteopontin and Stat3 signaling.
Yang F; Kalantari S; Ruan B; Sun S; Bian Z; Guan JL
Nat Commun; 2023 Feb; 14(1):978. PubMed ID: 36813768
[TBL] [Abstract] [Full Text] [Related]
9. MiR-130b modulates the invasive, migratory, and metastatic behavior of leiomyosarcoma.
Danielson LS; Guijarro MV; Menendez S; Higgins B; Sun Q; Mittal K; Popiolek DA; Overholtzer M; Palmer GD; Hernando E
PLoS One; 2023; 18(1):e0278844. PubMed ID: 36701370
[TBL] [Abstract] [Full Text] [Related]
10. Malignant perivascular epithelioid cell tumor (PEComa) of the uterus.
Cao B; Huang Y
BMC Womens Health; 2022 Dec; 22(1):523. PubMed ID: 36522714
[TBL] [Abstract] [Full Text] [Related]
11. Malignant Perivascular Epithelioid Cell Tumor (PEComa) of the Uterus as Part of the Hereditary Cancer Syndrome: A Case Diagnosed with Multiple Malignancies.
Caliskan S; Akar OS; Gun S; Kefeli M
Turk Patoloji Derg; 2023; 39(3):212-217. PubMed ID: 36367123
[TBL] [Abstract] [Full Text] [Related]
12. Uterine Leiomyosarcoma Masquerading as a Malignant Perivascular Epithelioid Cell Tumor: A Diagnostic Challenge.
Natsume T; Yoshida H; Nishikawa T; Kikkawa N; Naka T; Kobayashi-Kato M; Tanase Y; Uno M; Ishikawa M; Kato T
Int J Surg Pathol; 2023 Aug; 31(5):778-784. PubMed ID: 36310451
[TBL] [Abstract] [Full Text] [Related]
13. Temporary skin closure in extremity soft tissue sarcoma - our indications.
J M; P C; V Š; M F; Z M
Acta Chir Plast; 2022; 64(2):69-75. PubMed ID: 36068081
[TBL] [Abstract] [Full Text] [Related]
14. A Rare Cause of Chronic Hip Pain From PEComa: An Aggressive Mesenchymal Sarcoma.
Randhawa S; Pinsker J; Amirapu M; Sravanthi MV; Ashok Kumar P; Akhtar K
J Investig Med High Impact Case Rep; 2022; 10():23247096221103385. PubMed ID: 35699228
[TBL] [Abstract] [Full Text] [Related]
15. Phase II Study of TQB2450, a Novel PD-L1 Antibody, in Combination with Anlotinib in Patients with Locally Advanced or Metastatic Soft Tissue Sarcoma.
Liu J; Gao T; Tan Z; Li S; Xu J; Bai C; Xue R; Xie L; Zhang L; Fan Z; Guo W
Clin Cancer Res; 2022 Aug; 28(16):3473-3479. PubMed ID: 35675031
[TBL] [Abstract] [Full Text] [Related]
16. The therapeutic potential of RNA Polymerase I transcription inhibitor, CX-5461, in uterine leiomyosarcoma.
Kang CW; Hannan KM; Blackburn AC; Loh AHP; Hong KC; Yuan GJ; Hein N; Drygin D; Hannan RD; Coupland LA
Invest New Drugs; 2022 Jun; 40(3):529-536. PubMed ID: 35201535
[TBL] [Abstract] [Full Text] [Related]
17. HPV51-associated Leiomyosarcoma: A Novel Class of TP53/RB1-Wildtype Tumor With Predilection for the Female Lower Reproductive Tract.
Williams EA; Montesion M; Lincoln V; Tse JY; Hiemenz MC; Mata DA; Shah BB; Shoroye A; Alexander BM; Werth AJ; Foley-Peres K; Milante RR; Ross JS; Ramkissoon SH; Williams KJ; Adhikari LJ; Zuna RE; LeBoit PE; Lin DI; Elvin JA
Am J Surg Pathol; 2022 Jun; 46(6):729-741. PubMed ID: 35034043
[TBL] [Abstract] [Full Text] [Related]
18. Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in the Childhood Cancer Survivor Study.
Kim J; Gianferante M; Karyadi DM; Hartley SW; Frone MN; Luo W; Robison LL; Armstrong GT; Bhatia S; Dean M; Yeager M; Zhu B; Song L; Sampson JN; Yasui Y; Leisenring WM; Brodie SA; de Andrade KC; Fortes FP; Goldstein AM; Khincha PP; Machiela MJ; McMaster ML; Nickerson ML; Oba L; Pemov A; Pinheiro M; Rotunno M; Santiago K; Wegman-Ostrosky T; Diver WR; Teras L; Freedman ND; Hicks BD; Zhu B; Wang M; Jones K; Hutchinson AA; Dagnall C; Savage SA; Tucker MA; Chanock SJ; Morton LM; Stewart DR; Mirabello L
JNCI Cancer Spectr; 2021 Apr; 5(2):. PubMed ID: 34308104
[TBL] [Abstract] [Full Text] [Related]
19. Evolution of a melanoma in situ to a sarcomatoid dedifferentiated melanoma.
Chung J; Shevchenko A; Lee JB
J Cutan Pathol; 2021 Jul; 48(7):943-947. PubMed ID: 33675557
[TBL] [Abstract] [Full Text] [Related]
20. Translational Modeling of Anticancer Efficacy to Predict Clinical Outcomes in a First-in-Human Phase 1 Study of MDM2 Inhibitor HDM201.
Guerreiro N; Jullion A; Ferretti S; Fabre C; Meille C
AAPS J; 2021 Feb; 23(2):28. PubMed ID: 33554304
[TBL] [Abstract] [Full Text] [Related]
[Next]
